Type of Event: Earnings Conference Call, scheduled post the Board meeting.
Date and Time: The call will be held on 30th July 2026 at 16:30 hrs IST (19:00 hrs SST/HKT, 12:00 hrs BST, 07:00 hrs US ET).
Purpose: To discuss the company's Q1 FY 2027 unaudited financial results. The leadership team will discuss the financial performance and take questions from participants.
Timing Relative to Earnings: The call is scheduled after the Board meeting, which will approve the unaudited financial results for the quarter.
Management Participants: The document refers to the "leadership team" but does not specify individual names or designations.
Availability of Materials: A transcript of the conference call will be made available on the company's website (www.ajantapharma.com). Additionally, an audio playback of the call will be available on the website 120 minutes after the call ends.
UPSI Statement: The document does not contain any explicit statement regarding the sharing of unpublished price sensitive information (UPSI).
Additional Notes Section
Attachments: The letter mentions an enclosure ("Encl.: a/a"), but the nature of the attachment is not specified in the provided text.
Financial Data Disclosure: No financial figures, guidance, or strategic updates are disclosed in this announcement. It is purely a scheduling intimation for the earnings call.
Logistical Details: Detailed dial-in information and access instructions are provided for operational convenience, including international toll-free numbers for the USA, UK, Hong Kong, and Singapore, as well as primary access numbers and a Diamond pass registration link.
